GoldenGolden
Advanced Search
Novavax

Novavax

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

Novovax is a clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology. The company’s vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins that are critical to disease pathogenesis.

Novovirus generates their vaccine nanoparticles in insect cells. Cells of the fall armyworm, Spodoptera frugiperda, are grown as a cell line called Sf9. When infected with baculovirus, they have can continue to multiply indefinitely. The baculovirus is engineered to carry foreign genes to program the Sf9 cells to produce desired proteins. Recombinant proteins are designed to self-assemble into nanoparticle constructs in such a way as to elicit a strong immune response.

Novavax’s lead product is a nanoparticle flu vaccine called NanoFlu. The company developed vaccines for SARS and Middle East respiratory syndrome, that have not received regulatory approval. Novavax developed a RSV (respiratory syncytial virus) vaccine called ResVax that failed in two late-stage clinical studies. Novavax is working on a vaccine for the new coronavirus responsible for the COVID-19 outbreak.

Timeline

June 14, 2021
Novavax announces that it had completed a large efficacy trial of its COVID-19 vaccine.
May 21, 2021
Novavax announces that it receives 'Life Sciences Company of the Year' award from Maryland Tech Council.
April 13, 2021
Novavax announces promotion of Gale E. Smith, Ph.D to senior vice president and chief scientist in Discovery and Pre-clinical Reseach.
January 28, 2021
An experimental coronavirus vaccine developed by Novavax is 89.3 percent effective at preventing Covid-19.

Moderna announced this week that its vaccine appears to be less effective against the South African variant, although it said protective antibodies remained above protective levels.

November 9, 2020
Novavax appoints Gregory F. Covino as Chief Financial Officer.
May 26, 2020
Novavax announces it received $384 million from CEPI.
2020
Novavax announces starting human trials of a vaccine and expects to release a tested vaccine by this year.

Funding rounds

SBA Awards

Patents

Products

People

Name
Role
LinkedIn

Gregory Glenn, MD

President of Research and Development

Further reading

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
By VICTORIA MILKO
November 1, 2021
AP NEWS
JAKARTA, Indonesia (AP) -- Biotechnology company Novavax said Monday that Indonesia has given the world's first emergency use authorization for its COVID-19 vaccine, which uses a different technology than current shots.
August 9, 2021
The Indian Express
Worldwide, there is a gap between vaccine supply and demand, and disparities between developed and developing countries. Where will new vaccines come from, and what challenges must they meet?
FE Online
August 6, 2021
The Financial Express
SII has committed to supply 200 million doses of the Novavax vaccine between September and December 2021. Novavax said they were on track to achieve 100 million dose monthly capacity by the end of the third quarter of 2021 and 150 million dose monthly capacity by the end of the fourth quarter of 2021.
August 6, 2021
Hindustan Times
The J&J vaccine has been approved by several western countries and is in use in many of these, while the Novavax dose has shown some of the most promising results in clinical trials. | Latest News India
August 6, 2021
The News Minute
The Novavax announced that the two-dose shot, made with lab-grown copies of the spike protein that coats the coronavirus, had proved about 90% effective against symptomatic COVID-19.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.